about
Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazineA computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythmsSynergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.Advances in the Pharmacological Treatment of Atrial Fibrillation.Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparationsElectrophysiologic basis for the antiarrhythmic actions of ranolazine.Novel pharmacological targets for the rhythm control management of atrial fibrillation.Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalolAtrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.Role of late sodium channel current block in the management of atrial fibrillation.TASK-1 channels may modulate action potential duration of human atrial cardiomyocytesAtrial Fibrillation as a Prognostic Indicator in Medium to Large-Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure.Application of Traditional Chinese Medicine in Treatment of Atrial Fibrillation.Lone atrial fibrillation: what is known and what is to come.Mechanisms of termination and prevention of atrial fibrillation by drug therapy.Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.New directions in antiarrhythmic drug therapy for atrial fibrillation.Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.Ranolazine for the treatment of atrial fibrillation.QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double-blind, randomized, placebo-controlled trial.Isopimaric acid - a multi-targeting ion channel modulator reducing excitability and arrhythmicity in a spontaneously beating mouse atrial cell line.Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.Synthesis of a highly water-soluble acacetin prodrug for treating experimental atrial fibrillation in beagle dogs.Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria.Advances in the Pharmacologic Management of Atrial Fibrillation.Molecular basis for class Ib anti-arrhythmic inhibition of cardiac sodium channels.Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics.Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects.Aliskiren protecting atrial structural remodeling from rapid atrial pacing in a canine model.High uric acid level predicts left atrial thrombus or spontaneous echo contrast detected by transesophageal echocardiography: Meta-analysis and systematic review.
P2860
Q28293492-61D1BF4B-8E48-4832-B1F6-18D90C318117Q30513464-90CDE61D-8F62-4D76-89CF-870C190C6AFDQ34181734-D95A3543-F865-4C57-8C1A-262B87409255Q34383573-9A86E0F0-74E5-4119-8EC8-A0B757D9EB33Q34682939-89BFF8C0-3CA6-42C2-94C3-DD0CD8C34DEFQ35091243-1EA17F2C-D78E-4070-AB35-FC74C652AC3FQ35489060-AD2C2FFE-2C36-405F-ABD9-A8E808FE84FDQ35650683-BB6BB428-9750-4572-9A79-AB9E41A33933Q35897567-041B1F87-16B6-4575-B594-096A0B08A47CQ36013079-5B8D5767-07D9-48F8-B38A-FB381C397786Q36570112-585B8B3E-62F9-47D2-984C-EB5C81ABA528Q37005224-C68A40F4-52F2-4AC6-9E5C-5194E3BF13E5Q37020470-1886C9D1-EEA1-47C0-BDE0-1C19B07DD314Q37627515-A9A3837A-36C8-4DCA-BA3C-B971AA37FF84Q37827195-449E34B2-1385-44B0-AF1A-0AD3A3D44037Q37844891-A238CCA9-48F8-4333-9A61-20297B6E02AEQ37993754-7784ACBB-B291-4682-A50F-4B44553CB6E6Q38069201-871125D4-587A-4FDC-A258-62687315F56AQ38103541-C42D55E0-B22B-43B3-A9AF-E495A7DFD92CQ38420631-61AEBF30-DF86-4AED-8735-2A8C4F76B1DCQ38490444-D26CEEFB-66FD-4956-B520-2B18E8B5C1E2Q38703225-FFDF641E-3327-46CA-9EFA-AF1C351887EEQ39760319-FD61FBED-30A2-48B2-8F82-35203F094BB9Q41243959-26602FE9-C4B0-4B85-926A-C613FA15A673Q42432616-5388F26A-910C-4426-8B82-4C543BB15E59Q42777572-29E26E1E-9A3D-41B3-8E5D-2CE04DBBFA86Q43427939-51C1F2AE-B593-4768-AE9F-5BC7F626C0E1Q43920140-84E90E48-7BF0-48EE-A563-73551BE60F10Q51279498-5A896940-E72F-42EC-A2E7-9642870A9DC0Q53820825-22F53A00-6E38-4DF5-9291-6D34EAE3676DQ55027128-B0C3765E-2726-47E2-8C41-32B51A74CB00
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New developments in atrial antiarrhythmic drug therapy.
@en
New developments in atrial antiarrhythmic drug therapy.
@nl
type
label
New developments in atrial antiarrhythmic drug therapy.
@en
New developments in atrial antiarrhythmic drug therapy.
@nl
prefLabel
New developments in atrial antiarrhythmic drug therapy.
@en
New developments in atrial antiarrhythmic drug therapy.
@nl
P2860
P1476
New developments in atrial antiarrhythmic drug therapy.
@en
P2093
Alexander Burashnikov
P2860
P304
P356
10.1038/NRCARDIO.2009.245
P407
P577
2010-03-01T00:00:00Z